AGRX - Agile Therapeutics updates Q2 guidance

• Agile Therapeutics ( NASDAQ: AGRX ) updated its Q2 Twirla demand (total cycles) and operating expense guidance that was initially provided on May 24, 2022.
• Twirla demand is now seen to be at the mid-point of the earlier provided range (20K to 22K) of 21K to 21.5K cycles which marks a ~26% to 30% Q/Q growth.
• The updated Twirla demand guidance reflects continued progress made in both the retail and non-retail channels, with the non-retail channel showing significant Q/Q growth through its partnership with Afaxys.
• Earlier provided OPEX guidance was between $12.5 to $13.5M and is now seen to be below the low end of the earlier guided range.
• It expects OPEX to be in the range of $11.5 to 12.5M with change attributable to optimization of the Twirla sales force and marketing efforts to better focus on the most productive territories with high volume and favorable third-party reimbursement as well as the optimization of expense across all general and administrative area.
• Shares trading 1.1% higher premarket.

For further details see: